Pediatrix Medical Group (NYSE:MD) Price Target Raised to $15.00

Pediatrix Medical Group (NYSE:MD) had its target price increased by Deutsche Bank Aktiengesellschaft from $9.00 to $15.00 in a research note published on Monday morning, Benzinga reports. The firm currently has a hold rating on the stock.

MD has been the subject of several other research reports. StockNews.com raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. Jefferies Financial Group upgraded Pediatrix Medical Group from a “hold” rating to a “buy” rating and increased their target price for the stock from $8.00 to $14.00 in a research report on Thursday, September 26th. UBS Group lifted their target price on Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a research note on Friday, August 9th. Mizuho upped their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Monday. Finally, Truist Financial lifted their price objective on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research report on Monday. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $16.10.

Pediatrix Medical Group Stock Up 4.6 %

MD opened at $16.06 on Monday. The company has a current ratio of 1.42, a quick ratio of 1.38 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $1.38 billion, a PE ratio of -5.25, a PEG ratio of 2.35 and a beta of 1.55. Pediatrix Medical Group has a 1-year low of $6.62 and a 1-year high of $16.41. The firm’s 50 day simple moving average is $11.89 and its two-hundred day simple moving average is $9.54.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.29 earnings per share. As a group, equities analysts forecast that Pediatrix Medical Group will post 1.19 EPS for the current year.

Insider Activity

In related news, Director Laura A. Linynsky sold 7,000 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now owns 30,805 shares in the company, valued at approximately $343,783.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO James D. Swift sold 11,100 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the sale, the chief executive officer now directly owns 170,001 shares of the company’s stock, valued at $1,834,310.79. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Laura A. Linynsky sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the transaction, the director now directly owns 30,805 shares in the company, valued at approximately $343,783.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 68,100 shares of company stock worth $701,889. 1.20% of the stock is currently owned by insiders.

Institutional Trading of Pediatrix Medical Group

A number of institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets lifted its stake in Pediatrix Medical Group by 79.2% in the first quarter. BNP Paribas Financial Markets now owns 41,728 shares of the company’s stock worth $419,000 after purchasing an additional 18,438 shares during the last quarter. Empowered Funds LLC lifted its stake in shares of Pediatrix Medical Group by 8.2% during the 1st quarter. Empowered Funds LLC now owns 235,124 shares of the company’s stock worth $2,358,000 after acquiring an additional 17,784 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in Pediatrix Medical Group by 4.5% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 72,767 shares of the company’s stock valued at $730,000 after acquiring an additional 3,142 shares during the period. Illinois Municipal Retirement Fund boosted its holdings in Pediatrix Medical Group by 8.8% during the 1st quarter. Illinois Municipal Retirement Fund now owns 49,526 shares of the company’s stock valued at $497,000 after acquiring an additional 4,013 shares during the period. Finally, ProShare Advisors LLC grew its position in Pediatrix Medical Group by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 16,937 shares of the company’s stock valued at $170,000 after acquiring an additional 1,167 shares during the last quarter. 97.71% of the stock is currently owned by institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.